|
1
|
Wilhelm S, Carter C, Lynch M, Lowinger T,
Dumas J, Smith RA, Schwartz B, Simantov R and Kelley S: Discovery
and development of sorafenib: A multikinase inhibitor for treating
cancer. Nat Rev Drug Discov. 5:835–844. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Liu L, Cao Y, Chen C, Zhang X, McNabola A,
Wilkie D, Wilhelm S, Lynch M and Carter C: Sorafenib blocks the
RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor
cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer
Res. 66:11851–11858. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Llovet JM, Ricci S, Mazzaferro V, Hilgard
P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A,
et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J
Med. 359:378–390. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S,
Kim JS, Luo R, Feng J, Ye S, Yang TS, et al: Efficacy and safety of
sorafenib in patients in the asia-pacific region with advanced
hepatocellular carcinoma: A phase iii randomised, double-blind,
placebo-controlled trial. Lancet Oncol. 10:25–34. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kane RC, Farrell AT, Saber H, Tang S,
Williams G, Jee JM, Liang C, Booth B, Chidambaram N, Morse D, et
al: Sorafenib for the treatment of advanced renal cell carcinoma.
Clin Cancer Res. 12:7271–7278. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Keating GM and Santoro A: Sorafenib: A
review of its use in advanced hepatocellular carcinoma. Drugs.
69:223–240. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gauthier A and Ho M: Role of sorafenib in
the treatment of advanced hepatocellular carcinoma: An update.
Hepatol Res. 43:147–154. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Birt DF, Hendrich S and Wang W: Dietary
agents in cancer prevention: Flavonoids and isoflavonoids.
Pharmacol Ther. 90:157–177. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Huang YT, Hwang JJ, Lee PP, Ke FC, Huang
JH, Huang CJ, Kandaswami C, Middleton E Jr and Lee MT: Effects of
luteolin and quercetin, inhibitors of tyrosine kinase, on cell
growth and metastasis-associated properties in A431 cells
overexpressing epidermal growth factor receptor. Br J Pharmacol.
128:999–1010. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Leung HW, Wu CH, Lin CH and Lee HZ:
Luteolin induced DNA damage leading to human lung squamous
carcinoma ch27 cell apoptosis. Eur J Pharmacol. 508:77–83. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bagli E, Stefaniotou M, Morbidelli L,
Ziche M, Psillas K, Murphy C and Fotsis T: Luteolin inhibits
vascular endothelial growth factor-induced angiogenesis; inhibition
of endothelial cell survival and proliferation by targeting
phosphatidylinositol 3′-kinase activity. Cancer Res. 64:7936–7946.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lin Y, Shi R, Wang X and Shen HM:
Luteolin, a flavonoid with potential for cancer prevention and
therapy. Curr Cancer Drug Targets. 8:634–646. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yan J, Wang Q, Zheng X, Sun H, Zhou Y, Li
D, Lin Y and Wang X: Luteolin enhances tnf-related
apoptosis-inducing ligand's anticancer activity in a lung cancer
xenograft mouse model. Biochem Biophys Res Commun. 417:842–846.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Reipas KM, Law JH, Couto N, Islam S, Li Y,
Li H, Cherkasov A, Jung K, Cheema AS, Jones SJ, et al: Luteolin is
a novel p90 ribosomal S6 kinase (RSK) inhibitor that suppresses
Notch4 signaling by blocking the activation of Y-box binding
protein-1 (YB-1). Oncotarget. 4:329–345. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yang MY, Wang CJ, Chen NF, Ho WH, Lu FJ
and Tseng TH: Luteolin enhances paclitaxel-induced apoptosis in
human breast cancer MDA-MB-231 cells by blocking STAT3. Chem Biol
Interact. 213:60–68. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang X, Ju W, Renouard J, Aden J, Belinsky
SA and Lin Y: 17-allylamino-17-demethoxygeldanamycin
synergistically potentiates tumor necrosis factor-induced lung
cancer cell death by blocking the nuclear factor-kappab pathway.
Cancer Res. 66:1089–1095. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhao L, Wientjes MG and Au JL: Evaluation
of combination chemotherapy: Integration of nonlinear regression,
curve shift, isobologram, and combination index analyses. Clin
Cancer Res. 10:7994–8004. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Broecker-Preuss M, Müller S, Britten M,
Worm K, Schmid KW, Mann K and Fuhrer D: Sorafenib inhibits
intracellular signaling pathways and induces cell cycle arrest and
cell death in thyroid carcinoma cells irrespective of histological
origin or braf mutational status. BMC Cancer. 15:1842015.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bai L, Xu X, Wang Q, Xu S, Ju W, Wang X,
Chen W, He W, Tang H and Lin Y: A superoxide-mediated
mitogen-activated protein kinase phosphatase-1 degradation and
c-Jun NH(2)-terminal kinase activation pathway for luteolin-induced
lung cancer cytotoxicity. Mol Pharmacol. 81:549–555. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ju W, Wang X, Shi H, Chen W, Belinsky SA
and Lin Y: A critical role of luteolin-induced reactive oxygen
species in blockage of tumor necrosis factor-activated nuclear
factor-kappaB pathway and sensitization of apoptosis in lung cancer
cells. Mol Pharmacol. 71:1381–1388. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kurosu T, Ohki M, Wu N, Kagechika H and
Miura O: Sorafenib induces apoptosis specifically in cells
expressing BCR/ABL by inhibiting its kinase activity to activate
the intrinsic mitochondrial pathway. Cancer Res. 69:3927–3936.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bai L, Chen W, Wang X, Ju W, Xu S and Lin
Y: Attenuating smac mimetic compound 3-induced NF-kappaB activation
by luteolin leads to synergistic cytotoxicity in cancer cells. J
Cell Biochem. 108:1125–1131. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Attoub S, Hassan AH, Vanhoecke B, Iratni
R, Takahashi T, Gaben AM, Bracke M, Awad S, John A, Kamalboor HA,
et al: Inhibition of cell survival, invasion, tumor growth and
histone deacetylase activity by the dietary flavonoid luteolin in
human epithelioid cancer cells. Eur J Pharmacol. 651:18–25. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wagner EF and Nebreda AR: Signal
integration by jnk and p38 mapk pathways in cancer development. Nat
Rev Cancer. 9:537–549. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
25
|
Haagenson K and Wu GS: Mitogen activated
protein kinase phosphatases and cancer. Cancer Biol Ther.
9:337–340. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Choi AY, Choi JH, Yoon H, Hwang KY, Noh
MH, Choe W, Yoon KS, Ha J, Yeo EJ and Kang I: Luteolin induces
apoptosis through endoplasmic reticulum stress and mitochondrial
dysfunction in Neuro-2a mouse neuroblastoma cells. Eur J Pharmacol.
668:115–126. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ou DL, Shen YC, Yu SL, Chen KF, Yeh PY,
Fan HH, Feng WC, Wang CT, Lin LI, Hsu C and Cheng AL: Induction of
DNA damage-inducible gene GADD45beta contributes to
sorafenib-induced apoptosis in hepatocellular carcinoma cells.
Cancer Res. 70:9309–9318. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yu C, Friday BB, Lai JP, Yang L, Sarkaria
J, Kay NE, Carter CA, Roberts LR, Kaufmann SH and Adjei AA:
Cytotoxic synergy between the multikinase inhibitor sorafenib and
the proteasome inhibitor bortezomib in vitro: Induction of
apoptosis through Akt and c-Jun NH2-terminal kinase pathways. Mol
Cancer Ther. 5:2378–2387. 2006. View Article : Google Scholar : PubMed/NCBI
|
